Literature DB >> 23151852

Molecular dynamics and free energy studies of chirality specificity effects on aminobenzo[a]quinolizine inhibitors binding to DPP-IV.

Cui Wei1, Liang Desheng, Gao Jian, Luo Fang, Geng Lingling, Ji Mingjuan.   

Abstract

The aminobenzo[a]quinolizines were investigated as a novel class of DPP-IV inhibitors. The stereochemistry of this class plays an important role in the bioactivity. In this study, the mechanisms of how different configuration of three chiral centers of this class influences the binding affinity were investigated by molecular dynamics simulations, free energy decomposition analysis. The S configuration for chiral center 3* is decisive for isomers to maintain high bioactivity; the chirality effect of chiral center 2* on the binding affinity is largely dependent, while the S configuration for chiral center 2* is preferable to R configuration for the bioactivity gain; the effect of chiral center 11b* on the binding affinity is insignificant. The chirality specificity for three chiral centers is responsible for distinction of two van der Waals contacts with Tyr547 and Phe357, and of H-bonding interactions with Arg125 and Glu206. Particularly, the Arg125 to act as a bridge in the H-bonding network contributes to stable H-bonding interactions of isomer in DPP-IV active site.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23151852     DOI: 10.1007/s00894-012-1653-3

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  27 in total

1.  Converging free energy estimates: MM-PB(GB)SA studies on the protein-protein complex Ras-Raf.

Authors:  Holger Gohlke; David A Case
Journal:  J Comput Chem       Date:  2004-01-30       Impact factor: 3.376

2.  A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations.

Authors:  Yong Duan; Chun Wu; Shibasish Chowdhury; Mathew C Lee; Guoming Xiong; Wei Zhang; Rong Yang; Piotr Cieplak; Ray Luo; Taisung Lee; James Caldwell; Junmei Wang; Peter Kollman
Journal:  J Comput Chem       Date:  2003-12       Impact factor: 3.376

3.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

4.  Prediction of binding affinities between the human amphiphysin-1 SH3 domain and its peptide ligands using homology modeling, molecular dynamics and molecular field analysis.

Authors:  Tingjun Hou; William McLaughlin; Benzhuo Lu; Ken Chen; Wei Wang
Journal:  J Proteome Res       Date:  2006-01       Impact factor: 4.466

Review 5.  DPP IV inhibitors: successes, failures and future prospects.

Authors:  Ajay D Kshirsagar; Ashish S Aggarwal; Uday N Harle; Avinash D Deshpande
Journal:  Diabetes Metab Syndr       Date:  2012-04-05

Review 6.  Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.

Authors:  Shrikanth H Havale; Manojit Pal
Journal:  Bioorg Med Chem       Date:  2009-01-31       Impact factor: 3.641

7.  Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.

Authors:  Su-Jin Kim; Cuilan Nian; Doris J Doudet; Christopher H S McIntosh
Journal:  Diabetes       Date:  2008-02-25       Impact factor: 9.461

8.  Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.

Authors:  Jun Feng; Zhiyuan Zhang; Michael B Wallace; Jeffrey A Stafford; Stephen W Kaldor; Daniel B Kassel; Marc Navre; Lihong Shi; Robert J Skene; Tomoko Asakawa; Koji Takeuchi; Rongda Xu; David R Webb; Stephen L Gwaltney
Journal:  J Med Chem       Date:  2007-04-19       Impact factor: 7.446

9.  Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Authors:  Patrizio Mattei; Markus Boehringer; Patrick Di Giorgio; Holger Fischer; Michael Hennig; Joerg Huwyler; Buelent Koçer; Bernd Kuhn; Bernd M Loeffler; Alexander Macdonald; Robert Narquizian; Etienne Rauber; Elena Sebokova; Urs Sprecher
Journal:  Bioorg Med Chem Lett       Date:  2009-12-06       Impact factor: 2.823

10.  Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors.

Authors:  Markus Boehringer; Holger Fischer; Michael Hennig; Daniel Hunziker; Joerg Huwyler; Bernd Kuhn; Bernd M Loeffler; Thomas Luebbers; Patrizio Mattei; Robert Narquizian; Elena Sebokova; Urs Sprecher; Hans Peter Wessel
Journal:  Bioorg Med Chem Lett       Date:  2009-12-06       Impact factor: 2.823

View more
  2 in total

1.  Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4.

Authors:  Yongliang Gu; Wei Wang; Xiaolei Zhu; Keke Dong
Journal:  J Mol Model       Date:  2014-01-31       Impact factor: 1.810

2.  HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery.

Authors:  Lingling Geng; Zihua Wang; Xiangqian Jia; Qiuju Han; Zhichu Xiang; Dan Li; Xiaoliang Yang; Di Zhang; Xiangli Bu; Weizhi Wang; Zhiyuan Hu; Qiaojun Fang
Journal:  Theranostics       Date:  2016-05-28       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.